Drug Utilization Study for Pirinase Hayfever Relief

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Rhinitis, Allergic, Seasonal

Treatments: Drug: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray

Study type: Observational

Funder types: Industry

Identifiers

NCT02856282

205708

Details and patient eligibility

About

The purpose is to obtain real-world information on how consumers are complying with the product labelling This study will coincide with the launch of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray in the United Kingdom (UK).

Enrollment: 46 patients

Sex: All

Ages: 4 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants will be required to review, and electronically sign a Participation Agreement prior to completing the online survey.
• Participants of any age may participate.
• Participants who have purchased and used Pirinase Hayfever Relief for Adults 0.05% Nasal Spray for at least 7 days and are willing to participate in the online survey.
• Participants of either gender may participate

Exclusion criteria

• Anyone who is directly involved with medicines such as doctors, nurses, and pharmacists.
• Participants who decline participation in the online survey

Trial design

46 participants in 1 patient group

Pirinase Hayfever Relief for Adults 0.05% Nasal Spray

Description:

Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly

Treatment:

Drug: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray